
5 Things to Know About the CREATES Act
On June 14, 2018, the Senate Judiciary Committee voted 16 to 5 to report the Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act to the Senate floor. Here are 5 key things to know about the proposed legislation.
On June 14, 2018, the Senate Judiciary Committee voted 16 to 5 to report the Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act, which promotes price competition to lower costs of drugs, to the Senate floor.
Here are 5 key things to know about the proposed legislation.
1. The CREATES Act seeks to end “shenanigans” that delay competition from generic and biosimilar drugs.
Under the CREATES Act, a drug company can bring a civil action against an innovator drug company if the latter refuses to make available enough samples of a product for testing so that a biosimilar or generic can be developed. It also allows the FDA to approve alternative Risk Evaluation and Mitigation Strategy (REMS) programs if a generic or biosimilar developer and the innovator company are unable to arrive at a single shared system.
REMS Programs are designed to protect patient safety by restricting access to drugs that have special safety concerns and by requiring activities like provider training and patient counseling. However, abuse of REMS programs can halt generics and biosimilar development by keeping samples out of the hands of competitors. During a public workshop on drug pricing competition in November 2017, FDA Commissioner, Scott Gottlieb, MD, called these tactics “
2. Despite broad bipartisan support, the bill has struggled to reach a vote.
The legislation, sponsored by Senator Patrick Leahy, D-Vermont (with cosponsors
However, the bill languished without a vote as it faced opposition from pharmaceutical companies; The Hill
3. The legislation has support from a pioneer of the generics industry.
Among the most vocal supporters of the bill is former Representative Henry Waxman, D-California, who cosponsored (with Senator Orrin Hatch, R-Utah) the legal foundation for the US generics drug market: The Drug Price Competition and Patent Term Restoration Act of 1984, referred to colloquially as “Hatch-Waxman.”
Waxman
4. An amendment to the bill could limit options for generic and biosimilar developers, however.
Despite Waxman’s support for the legislation, his counterpart, Hatch, has concerns about the CREATES Act, and he has introduced an
Hatch’s amendment would prevent generic and biosimilar drug applicants from availing themselves of both standard litigation procedures (provided for under the Hatch-Waxman Act and the Biologics Price Competition and Innovation Act) and inter partes review (IPR) or post-grant review proceedings in seeking to invalidate patents on drugs.
Hatch said that the amendment would “…prevent companies from using IPR to put added litigation pressure on innovators above and beyond what Hatch-Waxman already provides. And it would prevent a company that rightfully loses a Hatch-Waxman suit from getting a second bite at the apple.”
5. Another amendment seeks to limit the applicability of the bill.
A second proposed amendment, BOM18329, introduced by John Cornyn, R-Texas, would
The legislation would therefore not impact manufacturers who use limited distribution networks (LDNs) to restrict the supply of their products to generic and biosimilar developers; writing in the April 2018 issue of AJMC®, Laura Karas, MD, MPH, and colleagues
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.